Topiramate - Revision history

MDElliottMD: parser-claude: Topiramate MedTemplate refill, Top 300 stub upgrade

2026-05-23T06:44:14Z

parser-claude: Topiramate MedTemplate refill, Top 300 stub upgrade

← Older revision		Revision as of 06:44, 23 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	\| generic = Topiramate		\| generic = Topiramate
	\| brand = Topamax		\| brand = Topamax (IR), Trokendi XR, Qudexy XR, Eprontia (oral solution); component of Qsymia (with phentermine)
	\| structure =		\| structure =
	\| classes = Anticonvulsant		\| classes = [[:Category:Anticonvulsants\|Anticonvulsant]], [[:Category:Migraine prophylactics\|Migraine prophylactic]], [[:Category:Weight loss medicines\|Weight loss medicine]], [[:Category:Sodium channel blockers\|Sodium channel blocker]]
	\| ~~mechanism =~~ Sodium channel blocker~~; AMPA antagonist; carbonic anhydrase inhibitor~~		\| uses = <vote slug="partial-seizures-monotherapy-use">Partial-onset seizures (FDA, monotherapy and adjunct)</vote>, <vote slug="generalized-tonic-clonic-use">Primary generalized tonic-clonic seizures (FDA, ages 2+)</vote>, <vote slug="lennox-gastaut-use">Lennox-Gastaut syndrome (FDA adjunct)</vote>, <vote slug="migraine-prophylaxis-use">Migraine prophylaxis (FDA, adult)</vote>, <vote slug="alcohol-use-disorder-topiramate-use">Alcohol use disorder (off-label, evidence-supported)</vote>, <vote slug="binge-eating-disorder-use">Binge-eating disorder and bulimia nervosa (off-label)</vote>, <vote slug="weight-loss-use">Chronic weight management (Qsymia combination with phentermine, FDA)</vote>
	\| uses =		\| starting_dose = Migraine: 25 mg PO at bedtime, titrate by 25 mg weekly to target 100 mg/day divided BID. Seizures: 25-50 mg/day, titrate weekly to 200-400 mg/day divided BID
	\| starting_dose =		\| preparations = IR tablets 25, 50, 100, 200 mg; sprinkle capsules 15, 25 mg; Trokendi XR capsules 25, 50, 100, 200 mg; Qudexy XR capsules; Eprontia oral solution 25 mg/mL
	\| preparations =		\| fda_max = 1600 mg/day (theoretical seizure dosing); practical use 400 mg/day for seizures, 100-200 mg/day for migraine prophylaxis
	\| fda_max =		\| pill_id =
	\| routes =		\| routes = Oral
	\| onset =		\| onset = Anticonvulsant effect within days at therapeutic level; migraine prophylaxis effect emerges over 2-3 months
	\| duration =		\| duration = 12-24 hours (IR BID); 24 hours (ER once-daily)
	\| halflife =		\| halflife = ~21 hours<ref name="topamax-label">FDA Prescribing Information, Topamax (topiramate), Janssen, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020844s050lbl.pdf</ref>
	~~\| bioavailability =~~		\| bioavailability = ~80% (oral)<ref name="topamax-label" />
	~~\| pregnancy~~ =		\| pregnancy = '''Substantial teratogenic risk''' including cleft lip/palate, hypospadias, and growth restriction (pregnancy registry data clear); effective contraception and pre-pregnancy counseling are required in reproductive-age patients<ref name="topamax-label" />
	~~\| legal~~ =		\| legal = [[USLegal:Prescription only\|Rx-only]] in US. Not a controlled substance<ref name="topamax-label" />
	\| ~~intro~~ =		\| mechanism = <vote slug="topiramate-mech-claim">Multi-target anticonvulsant: voltage-gated sodium channel blocker in the inactivated state, GABA-A receptor potentiator at a non-benzodiazepine site, AMPA/kainate glutamate receptor antagonist, and weak carbonic anhydrase inhibitor. The carbonic anhydrase inhibition explains the characteristic adverse-effect cluster (paresthesias, metabolic acidosis, kidney stones, oligohidrosis with heat intolerance) and likely contributes to the cognitive slowing nicknamed "dopamax" in clinical lore.</vote> Weight loss is a class effect, the basis of the Qsymia combination with phentermine for chronic weight management. Carbonic-anhydrase-related '''acute angle-closure glaucoma''' is a rare but vision-threatening idiosyncratic reaction, typically within the first month<ref name="topamax-label" />.
	~~\| pharmacokinetics~~ =
	\| ~~pharmacodynamics~~ =
	~~\| indications~~ =
	\| ~~dosing~~ =
	\| ~~effects =~~
	~~\| interactions~~ = ~~<pharmaInteractions~~/>
	\| ~~pregnancy_details =~~
	~~\| monitoring~~ =
	~~\| counseling~~ =
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references~~ =
	}}		}}

	[[Category:~~Antiepileptics~~]]		== References ==
	[[Category:~~Carbonic anhydrase inhibitors~~]]		<references />

			[[Category:Anticonvulsants]]
			[[Category:Migraine prophylactics]]
			[[Category:Weight loss medicines]]
			[[Category:Sodium channel blockers]]

MDElliottMD: Category taxonomy ship: retag Anticonvulsants -> Antiepileptics

2026-05-22T00:37:34Z

Category taxonomy ship: retag Anticonvulsants -> Antiepileptics

← Older revision		Revision as of 00:37, 22 May 2026
Line 31:		Line 31:
	}}		}}

	[[Category:~~Anticonvulsants~~]]		[[Category:Antiepileptics]]
	[[Category:Carbonic anhydrase inhibitors]]		[[Category:Carbonic anhydrase inhibitors]]

MDElliottMD: Dedupe migration per interface-claude 2026-05-20: Anticonvulsants / Antiepileptics merged into canonical Anticonvulsants. Member retagged.

2026-05-19T18:00:15Z

Dedupe migration per interface-claude 2026-05-20: Anticonvulsants / Antiepileptics merged into canonical Anticonvulsants. Member retagged.

← Older revision		Revision as of 18:00, 19 May 2026
Line 31:		Line 31:
	}}		}}


	~~[[Category:Anticonvulsants / Antiepileptics]]~~
	[[Category:Anticonvulsants]]		[[Category:Anticonvulsants]]
	[[Category:Carbonic anhydrase inhibitors]]		[[Category:Carbonic anhydrase inhibitors]]

MDElliottMD: Comprehensive categorization: +Carbonic anhydrase inhibitors

2026-05-15T18:42:21Z

Comprehensive categorization: +Carbonic anhydrase inhibitors

← Older revision		Revision as of 18:42, 15 May 2026
Line 34:		Line 34:
	[[Category:Anticonvulsants / Antiepileptics]]		[[Category:Anticonvulsants / Antiepileptics]]
	[[Category:Anticonvulsants]]		[[Category:Anticonvulsants]]
			[[Category:Carbonic anhydrase inhibitors]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:07:04Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:07, 14 May 2026
Line 31:		Line 31:
	}}		}}


			[[Category:Anticonvulsants / Antiepileptics]]
	[[Category:Anticonvulsants]]		[[Category:Anticonvulsants]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:31:11Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:31, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:52Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:32:52Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:32, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Anticonvulsants]]		[[Category:Anticonvulsants]]

MDElliottMD: Expand stub to full MedTemplate parameter set

2026-05-13T01:00:00Z

Expand stub to full MedTemplate parameter set

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Topiramate
+| generic            = Topiramate
-| brand             = Topamax
+| brand              = Topamax
-| classes           = Anticonvulsant
+| structure          =
-| mechanism         = Sodium channel blocker; AMPA antagonist; carbonic anhydrase inhibitor
+| classes            = Anticonvulsant
 }}
 [[Category:Anticonvulsants]]

MDElliottMD: Auto-created stub

2026-05-13T00:00:00Z

Auto-created stub

New page

{{MedTemplate
| generic = Topiramate
| brand = Topamax
| classes = Anticonvulsant
| mechanism = Sodium channel blocker; AMPA antagonist; carbonic anhydrase inhibitor
}}
[[Category:Anticonvulsants]]